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background: The Fluoropyrimidines (FP), 5-Fluorouracil (5FU) and capecitabine (CAP), remain among the most commonly used chemotherapy. 
Previously published studies that examined the role of FP with cardiac events have reported inconsistent results regarding adverse events with 
treatment and clinical outcome. In this study, the medical literature was systematically reviewed for clinical trials to summarize the effect of 
chemotherapy with use of FP and to further identify differences in clinical outcome for both 5FU and CAP.
methods: A search in Medline and the Cochrane Central Register of Controlled Trials (from January 1985 to December 2010) was performed to 
identify randomized controlled studies designed to evaluate cardiac adverse effects with treatment and clinical outcome of patients undergoing 
chemotherapy. Cardiac ischemia reported as angina, ischemic ECG changes, myocardial infarction, and elevated biomarkers was the primary 
outcome variable. Data was extracted on all grades of cardiac adverse events, time to reported cardiac event, type of malignancy and pre-existing 
heart disease.
results: Of 84 publications identified, only 11 (n=4330) fulfilled selection criteria. Cumulative incidence of cardiac ischemia for duration of study 
was found to be 0.3% -18.6%. A pooled analysis revealed that 3.1% of patients (n=133) showed manifestations of cardiac ischemia. 81 patients 
had evidence of ischemic ECG changes. 12 cardiac deaths were reported. 2% (18/917) of patients in the CAP group, and 3.4% (115/3413) in the 
5FU group suffered from manifestations of cardiac ischemia (p=0.031).
Conclusion: Clinical and research protocols exist regarding monitoring for cardiotoxicity with anthracyclines, but do not exist for FP’s. Our 
systematic review suggests that cardiac ischemia in this group is significant. In patients with risk factors for heart disease, the use of CAP over 5FU 
should be considered as the preferred chemotherapeutic agent.
